Fig. 4

Effect of glepaglutide co-treatment or post-treatment on jejunal and ileal inflammatory markers during active inflammation. Effect of glepaglutide (400 nmol/kg, SC, twice daily) administered in a co-treatment or post-treatment regimen on A jejunal and B ileal α-1-AGP concentrations (ng/mg protein), and C jejunal and D ileal MPO concentrations (ng/mg protein), in the active inflammation phase (2–3 days after inflammation onset) in Wistar rats with small intestinal inflammation. *p ≤ 0.05, **p < 0.01, ***p < 0.001 vs INDO controls. Data shown are mean ± SEM. α-1-AGP, α-1-acid glycoprotein; INDO, indomethacin; MPO, myeloperoxidase; SC, subcutaneously; SEM, standard error of the mean